Helix BioPharma Files Interim Financial Statements for Q1 2026, Highlighting Oncology Pipeline Progress

Helix BioPharma Corp., a clinical-stage oncology company focused on developing treatments for hard-to-treat cancers, announced the filing of its unaudited interim financial statements as of and for the three-month period ended October 31, 2025. The filing includes the financial statements, management's discussion and analysis, and certifications from the Chief Executive Officer and Chief Financial Officer. These documents are collectively referred to as the Interim Filings and represent the company's first financial reporting for its 2026 fiscal year. The availability of these filings provides investors and stakeholders with current financial information about the company's operations and capital position during a period of ongoing clinical development.

The Interim Filings are accessible through regulatory channels and the company's website, offering transparency about Helix BioPharma's financial status as it advances its oncology pipeline. Investors can review the documents on the company's profile at https://www.sedarplus.ca and on its corporate website at https://www.helixbiopharma.com/filings-and-financials/. This regular financial reporting is particularly important for publicly traded companies like Helix BioPharma, which is listed on multiple exchanges including TSX, OTC PINK, and FWB. The filings allow market participants to assess the company's financial health and resource allocation as it progresses its clinical programs.

Helix BioPharma's pipeline features several promising oncology candidates, with Tumor Defense Breaker™ L-DOS47 as its lead clinical-stage program. This antibody-enzyme conjugate targets CEACAM6-expressing tumors and has completed Phase Ib studies in non-small cell lung cancer. The company is also developing next-generation bi-specific antibody-drug conjugates that share the same CEACAM6-targeting foundation. Additionally, Helix advances two pre-IND candidates: LEUMUNA™, an oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a first-in-class oral gemcitabine prodrug designed to expand treatment options for advanced cancers. These programs represent the company's strategic focus on addressing significant unmet medical needs in oncology.

The financial statements include forward-looking statements that outline the company's expectations regarding future business operations, research and development activities, and potential benefits of its programs. These statements are based on estimates and assumptions that management considers reasonable but are subject to various risks and uncertainties. Factors that could affect actual results include the accuracy of the company's assumptions, its ability to capitalize on potential benefits, and other risk factors detailed in periodic reports available on its SEDAR+ profile. The company notes there is no assurance that anticipated events will transpire as expected or that proposed transactions will be completed according to their terms or at all.

This financial filing occurs as Helix BioPharma continues to position itself as a company working toward near-term solutions for challenging cancers. The interim financial reporting provides stakeholders with updated information about the company's financial position during a critical development phase for its oncology pipeline. Regular disclosure of financial information supports market transparency and informed investment decisions, particularly for companies in the capital-intensive biopharmaceutical sector where clinical development timelines are extended and resource requirements are substantial. The filings represent a routine but essential aspect of corporate governance and investor communication for publicly listed biotechnology companies advancing novel therapeutic approaches.